Clinical trial
The Safety and Feasibility of Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma：A Phase 1 Trial
NCT06654297 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Feasibility of Neoadjuvant Camrelizumab With Palbociclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma：A Phase 1 Trial
- Lead sponsor
- West China Hospital
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 27, 2024
- Completion date
- February 7, 2027
- Enrollment
- 6 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.